Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

COX-2 inhibitors are contraindicated for treatment of combined injury.

Jiao W, Kiang JG, Cary L, Elliott TB, Pellmar TC, Ledney GD.

Radiat Res. 2009 Dec;172(6):686-97. doi: 10.1667/RR1581.1.

PMID:
19929415
2.

Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors.

Nakata E, Mason KA, Hunter N, Husain A, Raju U, Liao Z, Ang KK, Milas L.

Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):369-75.

PMID:
14751505
3.

New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra).

Cotter J, Wooltorton E.

CMAJ. 2005 May 10;172(10):1299. Epub 2005 Apr 15. No abstract available.

4.

Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.

Yasumaru M, Tsuji S, Tsujii M, Irie T, Komori M, Kimura A, Nishida T, Kakiuchi Y, Kawai N, Murata H, Horimoto M, Sasaki Y, Hayashi N, Kawano S, Hori M.

Cancer Res. 2003 Oct 15;63(20):6726-34.

5.

Aggravation by selective COX-1 and COX-2 inhibitors of dextran sulfate sodium (DSS)-induced colon lesions in rats.

Okayama M, Hayashi S, Aoi Y, Nishio H, Kato S, Takeuchi K.

Dig Dis Sci. 2007 Sep;52(9):2095-103. Epub 2007 Apr 12.

PMID:
17429720
6.

[Safety of celecoxib administration].

Babić-Naglić D.

Reumatizam. 2002;49(2):26-8. Croatian.

PMID:
12476757
7.

Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature.

Davis TW, O'Neal JM, Pagel MD, Zweifel BS, Mehta PP, Heuvelman DM, Masferrer JL.

Cancer Res. 2004 Jan 1;64(1):279-85.

8.

Blocking prostaglandin E2 after trauma attenuates pro-inflammatory cytokines and improves survival.

Strong VE, Mackrell PJ, Concannon EM, Naama HA, Schaefer PA, Shaftan GW, Stapleton PP, Daly JM.

Shock. 2000 Sep;14(3):374-9.

PMID:
11028559
9.

Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor.

Kishi K, Petersen S, Petersen C, Hunter N, Mason K, Masferrer JL, Tofilon PJ, Milas L.

Cancer Res. 2000 Mar 1;60(5):1326-31.

10.

Cyclooxygenase (COX)-2-dependent effects of the inhibitor SC236 when combined with ionizing radiation in mammary tumor cells derived from HER-2/neu mice.

Lanza-Jacoby S, Dicker AP, Miller S, Rosato FE, Flynn JT, Lavorgna SN, Burd R.

Mol Cancer Ther. 2004 Apr;3(4):417-24.

11.

Analgesia and COX-2 inhibition.

Dionne RA, Khan AA, Gordon SM.

Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S63-70. Review.

PMID:
11695255
12.

Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.

Moore PA, Hersh EV.

J Am Dent Assoc. 2001 Apr;132(4):451-6. Review.

PMID:
11315375
15.

COX-2 inhibitors.

Crowther CL.

Lippincotts Prim Care Pract. 1999 Jul-Aug;3(4):394-6. Review. No abstract available.

PMID:
10624270
16.

Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers.

Brzozowski T, Konturek PC, Konturek SJ, Sliwowski Z, Pajdo R, Drozdowicz D, Ptak A, Hahn EG.

Microsc Res Tech. 2001 Jun 1;53(5):343-53.

PMID:
11376495
17.

Celecoxib and radiation therapy in non-small-cell lung cancer.

Gore E.

Oncology (Williston Park). 2004 Dec;18(14 Suppl 14):10-4. Review.

18.

COX-2 specific inhibitors offer improved advantages over traditional NSAIDs.

Urban MK.

Orthopedics. 2000 Jul;23(7 Suppl):S761-4. Review.

PMID:
10914695
19.

Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor.

Muscará MN, McKnight W, Asfaha S, Wallace JL.

Br J Pharmacol. 2000 Feb;129(4):681-6.

20.

In vivo selectivity of a selective cyclooxygenase 2 inhibitor in the oral surgery model.

Khan AA, Brahim JS, Rowan JS, Dionne RA.

Clin Pharmacol Ther. 2002 Jul;72(1):44-9.

PMID:
12152003
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk